Over the last decade, compelling evidence has shown that cancer stem cells (CSCs) exist in a variety of malignancies. The conventional method for anticancer therapy involves targeting only the proliferating mitotic cells, sparing the slow-cycling cells that eventually evade chemotherapy and become a source of post therapy relapses. With the increasing awareness of CSCs supported by sophisticated experimental evidence, therapeutic strategies today are aimed at selectively identifying and targeting CSCs using biomarkers. The ability to identify CSCs allows targeted elimination of these cancer-initiating cells. Herein, we discuss CSC markers in the context of different types of cancers, their significance in selectively identifying CSCs and the therapeutic implications of using these biomarkers to prevent invasion and metastasis of cancer.

The present study aims to evaluate the inhibition effectiveness of titanium dioxide nanoparticles in combination with cell wall active antibiotics -ceftazidime and cefotaxime against the multi-drug resistant Pseudomonas aeroginosa isolated from pus, sputum, endo-tracheal tract and broncho-alveolar lavage. Commercial Degussa-P25 TiO 2 nanoparticle, antibiotics ceftazidime and cefotaxime were used in this study against multi-drug-resistant nosocomial pathogen. The nanoparticle shows antimicrobial effect on the pathogen at concentrations more than 350 mg/mL, when exposed to ultraviolet (UV) light for an hour. Minimum inhibitory concentration values obtained for the antibiotic cefotaxime were sixfolds higher than the antibiotic ceftazidime. When these antibiotics were used in combination with UV-irradiated metal nanoparticle, ceftazidime resulted in enhanced antimicrobial activity whereas cefotaxime does not show any change.

Nanomedicine involves the use of nanotechnology for clinical applications and holds promise to improve treatments. Recent developments offer new hope for cancer detection, prevention and treatment; however, being a heterogenous disorder, cancer calls for a more targeted treatment approach. Personalized Medicine (PM) aims to revolutionize cancer therapy by matching the most effective treatment to individual patients. Nanotheranostics comprise a combination of therapy and diagnostic imaging incorporated in a nanosystem and are developed to fulfill the promise of PM by helping in the selection of treatments, the objective monitoring of response and the planning of follow-up therapy. Although well-established imaging techniques, such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), are primarily used in the development of theranostics, Optical Imaging (OI) offers some advantages, such as high sensitivity, spatial and temporal resolution and less invasiveness. Additionally, it allows for multiplexing, using multi-color imaging and DNA barcoding, which further aids in the development of personalized treatments. Recent advances have also given rise to techniques permitting better penetration, opening new doors for OI-guided nanotheranostics. In this review, we describe in detail these recent advances that may be used to design and develop efficient and specific nanotheranostics for personalized cancer drug delivery.

The concept of selective tumor targeting using nanomedicines has been around for decades, however, no targeted nanoparticle has yet reached the clinic. A key bottleneck is the non-selectivity of targeted...